Rautenstrauch H, Laschner W, Saal J G, Fritz P
Z Rheumatol. 1986 Nov-Dec;45(6):319-21.
In 34 patients with severe rheumatoid arthritis the therapeutic efficacy of 600 mg/die of D-penicillamine was evaluated for five years. Patients were included in the study only if the duration of their disease exceeded 6 months (upper limit 12 months), and there was involvement of 6 or more joints and an elevated erythrocyte sedimentation rate (1 Hour values greater than or equal to 25 mm). In 9 patients (26%) a decline in the activity index could be observed, but 7 of these subjects had a deterioration of findings as assessed by x-ray. The increase of the activity index indicated no therapeutic benefit in 25 patients (74%), which could be confirmed in all subjects by x-ray.
对34例重症类风湿性关节炎患者评估了每日600毫克青霉胺的治疗效果，为期五年。仅当患者病程超过6个月（上限为12个月）、累及6个或更多关节且红细胞沉降率升高（1小时值大于或等于25毫米）时，才纳入研究。9例患者（26%）的活动指数有所下降，但其中7例经X线评估病情恶化。25例患者（74%）的活动指数升高表明无治疗益处，所有患者的X线检查均证实了这一点。
